Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of IMM01 plus azacitidine in treatment-naive CMML
CTR20243920Phase 3Active
- Sponsor
- ImmuneOnco
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of timdarpacept, azacitidine in chronic myelomonocytic leukemia (CMML), sponsored by ImmuneOnco. Started Nov 2024; status: active.
02
Drugs
timdarpaceptazacitidine
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on CTR20243920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243920.